Validating biomarkers for effective drug development
Track 4: Auto Antibodies Auto-antibody is an antibody formed in response to, and reacting against, an antigenic constituent of the individual's own tissues.Several mechanisms may trigger the production of autoantibodies: an antigen, formed during fetal development and then sequestered, may be released as a result of infection, chemical exposure or trauma, as occurs in autoimmune thyroiditis, sympathetic uveitis and aspermia; there may be disorders of immune regulatory or surveillance function; antibodies produced against certain streptococcal antigens during infection may cross-react with myocardial tissue, causing rheumatic heart disease, or with glomerular basement membrane, causing glomerulonephritis; and normal body proteins may be converted to auto-antigens by chemicals, infectious organisms, or therapeutic drugs.
Antibody Profiling is used for identifying persons from forensic samples.If human antibodies are to be used, then one would like to understand the basis by which different isotypes interact with host effector systems, and if possible, improve on nature by engineering in desirable modifications.Track 3: Antibodies: Infectious Diseases The evidence indicates that two simian immunodeficiency viruses (SIV), one from Chimpanzees (SIVcpz) and the other from sooty mangabeys (SIVsm), crossed the species barrier to humans, generating HIV-1 and HIV-2, respectively.They can be made in large quantities in the laboratory and are a cornerstone of immunology.They are used to treat many diseases, including some types of cancer.They target various proteins that influence cell activity such as receptors or other proteins present on the surface of normal and cancer cells.
The specificity of Monoclonal Antibodies allows it’s binding to cancerous cells by coupling a cytotoxic agent such as a strong radioactive which then seeks out to destroy the cancer cells while not harming the healthy ones.
Our experienced project management teams are available to provide support and guidance from initial biomarker selection through to the design of a comprehensive results data package to deliver against your project aims and timelines.
RCLS’s flexibility through our custom in house development service and extensive range of off the shelf products enables our clients to meet challenging projects with tailored, cost effective and rapid solutions.
The immune system ceases to recognize one or more of the body's normal constituents as "self," leading to production of pathological auto antibodies.
These auto antibodies attack the body's own healthy cells, tissues, and/or organs, causing inflammation and damage.
Related Conferences: 4 European Immunology Conference, June 29-July 01, 2017 Madrid, Spain.